#Australia #Sydney #Clarity Pharmaceuticals #SECuRE Trial #67Cu-SAR-bisPSMA

Clarity Pharmaceuticals Updates on SECuRE Trial

Clarity Pharmaceuticals, a leader in clinical-stage radiopharmaceuticals, recently announced an update regarding their SECuRE trial, focusing on the 8 GBq dose of 67Cu-SAR-bisPSMA. This update highlights the encouraging efficacy and safety profile observed within the trial, offering hope for advanced prostate cancer patients.

The SECuRE trial (NCT04868604) aims to assess the potential of 67Cu-SAR-bisPSMA, particularly among patients with metastatic castration-resistant prostate cancer (mCRPC). The latest findings come from a preliminary assessment involving 19 participants who either received the 67Cu-SAR-bisPSMA treatment in the Cohort Expansion phase or had previously been part of the Dose Escalation phase. Most of these patients had extensive treatment histories, with 79% reporting five or more anticancer therapies prior to enrollment.

Patient Population and Treatment Details

The trial's participant population is notable, with 63% suffering from bone metastases. These individuals faced significant challenges, having undergone multiple previous treatments, including androgen deprivation therapy and newer ARPI therapies. On average, participants in this latest assessment received approximately two treatment cycles of the 67Cu-SAR-bisPSMA at the 8 GBq level. Overall, the preliminary results from the trial indicate a substantial response to treatment, with significant declines in prostate-specific antigen (PSA) levels being observed:

• - PSA50: 63% of participants achieved a 50% reduction in PSA levels.
• - PSA25: A remarkable 74% achieved reductions of at least 25%.
• - PSA90: Approximately 26% reached a 90% drop in PSA levels.

Radiographic assessments showed that out of 16 evaluable participants, 81% had their disease controlled, comprising a mix of stable disease and complete responses, representing a clear indication of the treatment's efficacy. Remarkably, two participants achieved complete responses by RECIST criteria, raising the total to seven participants across the 67Cu-SAR-bisPSMA program who achieved either a complete response or undetectable disease.

Safety Profile of 67Cu-SAR-bisPSMA

The safety profile of the 67Cu-SAR-bisPSMA treatment remains favorable, with adverse events primarily being mild to moderate. Participants reported common issues such as dry mouth and nausea, but the severity and frequency were generally lower compared to typical treatments in this patient population. Most participants tolerated the treatments well, which highlights the potential for 67Cu-SAR-bisPSMA as a viable option for patients with limited treatment alternatives.

Clarity Pharmaceuticals' Executive Chairperson, Dr. Alan Taylor, expressed optimism regarding these findings, stating that the emerging data demonstrates important anti-tumor activity despite a relatively small sample size of participants treated. He emphasized the importance of this innovation, noting how it could potentially reshape treatment paradigms for prostate cancer patients in various stages of their disease.

Future Directions for the SECuRE Trial

The SECuRE trial is set to continue recruiting patients for the Cohort Expansion Phase, with a Phase III registrational trial anticipated to follow based on the ongoing positive data outputs. Clarity Pharmaceuticals aims to broaden the impact of 67Cu-SAR-bisPSMA and further solidify its role in the therapeutic landscape of prostate cancer treatment. The company is committed to exploring the full potential of SAR-bisPSMA, which uniquely combines diagnostic and therapeutic potential within one molecule, promising improved outcomes for patients battling prostate cancer.

As the trial progresses, stakeholders, including oncologists and patients alike, will eagerly await further results that could confirm the utility of 67Cu-SAR-bisPSMA in clinical practice, ultimately impacting the lives of countless prostate cancer patients globally.